Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity by Stish, B J et al.
Design and modification of EGF4KDEL 7Mut, a novel bispecific
ligand-directed toxin, with decreased immunogenicity and potent
anti-mesothelioma activity
BJ Stish
1,SO h
1, H Chen
1, AZ Dudek
2, RA Kratzke
2 and DA Vallera*,1
1Department of Therapeutic Radiology-Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota,
Minneapolis, MN, USA;
2Department of Medicine, University of Minnesota, Minneapolis, MN, USA
BACKGROUND: Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy.
METHODS: To address potency, we used genetic engineering to develop a novel bispecific ligand-directed toxin (BLT) called
EGF4KDEL, a novel recombinant anti-mesothelioma agent created by linking human epidermal growth factor (EGF) and interleukin-4
(IL-4) to truncated pseudomonas exotoxin (PE38) on the same single-chain molecule. Immunogenicity was reduced by mutating
seven immunodominant B-cell epitopes on the PE38 molecule to create a new agent, EGF4KDEL 7Mut.
RESULTS: In vitro, bispecific EGF4KDEL showed superior anti-mesothelioma activity compared with its monospecific counterparts.
Toxicity in mice was diminished by having both ligands on the same molecule, allowing administration of a 10-fold greater dose of
BLT than a mixture of monomeric IL4KDEL and EGFKDEL. EGF4KDEL 7Mut, retained all of its functional activity and induced about
87% fewer anti-toxin antibodies than mice given the parental, non-mutated form. In vivo, intraperitoneal (IP) injection of the BLT
showed significant (Po0.01) and impressive effects against two aggressive, malignant IP mesothelioma models when treatment was
begun 14–16 days post tumour innoculation.
CONCLUSION: These data show that EGF4KDEL 7Mut is a promising new anti-mesothelioma agent that was developed to specifically
address the obstacles facing clinical utility of targeted toxins.
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Malignant mesothelioma (MM) is a highly aggressive cancer of the
serosal surfaces of the body with an invariably poor prognosis
(Zucali and Giaccone, 2006). Owing to the inherent properties of
MM, surgical resection or radiotherapeutic intervention are often
not viable treatment options (Palumbo et al, 2008). Combination
therapy with pemetrexed and cisplatin, the current standard of
therapy for nonresectable MM, results in a median survival time of
only 12.1 months and has many treatment-associated side effects
(Vogelzang et al, 2003; Simon et al, 2008). With 15000–20000
deaths per year worldwide due to MM, new and improved
therapies are desperately needed (Zervos et al, 2008).
Specifically targeting overexpressed cell surface receptors on
tumour cells offers a promising alternative approach for MM
therapy (Hassan et al, 2007). Ligand-directed cytotoxins contain-
ing a truncated pseudomonas exotoxin A (PE38) are a unique class
of receptor-targeted biological drugs with extremely potent anti-
cancer activity (Kreitman and Pastan, 1998). PE38 is used for
cytotoxin construction because a single molecule delivered to the
cytosol is sufficient to bring about cell killing by catalysing ADP
ribosylation of elongation factor 2 (EF-2) leading to irreversible
inhibition of protein synthesis and cell death (Pastan et al, 1992).
Further studies have shown that modifying PE38 by adding a
Lys-Asp-Glu-Leu (KDEL) C-terminal signal that prevents secretion
of luminal endoplasmic reticulum (ER) proteins increased ER
accumulation and enhanced potency of targeted toxins (Kreitman
and Pastan, 1995). The advantage of ligand-directed toxins is that
PE38KDEL-mediated cytotoxicity requires specific ligand-receptor
binding and subsequent internalisation. This allows maximal anti-
cancer activity while limiting collateral killing of normal cells.
Previous research has shown overexpression of epidermal
growth factor receptor (EGFR) on most MM cell lines and clinical
tumour samples (Cole et al, 2005; Govindan et al, 2005). Activation
of EGFR promotes processes responsible for tumour growth and
progression, including proliferation and maturation, angiogenesis,
invasion, metastasis, and inhibition of apoptosis, making it a
popular target for anti-cancer therapy (Yarden and Sliwkowski,
2001). Immunohistochemistry studies have also shown high
expression levels of interleukin-4 receptor (IL-4R) on patient
mesothelioma samples (Beseth et al, 2004). Interleukin-4 is an
important cytokine in Th2 differentiation of T cells and IL-4R has
proven to be a promising target for treatment of pancreatic cancer
and glioblastoma (Rand et al, 2000; Shimamura et al, 2007). To
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senhance the activity of cytotoxins targeting IL-4R, a circularly
permuted IL-4 cytotoxin has been described that improved
binding site exposure without altering ligand-receptor specificity
(Kreitman et al, 1994) and these alterations were incorportated
into EGF4KDEL. Both EGFR and IL-4R are ideal targets for ligand-
directed toxin therapies as both are cell surface molecules that
internalise rapidly upon ligand binding (Haigler et al, 1978;
Kawakami et al, 2002a).
Targeting solid tumours with ligand-directed cytotoxins has
been hampered by problems with immunogenicity as effective
therapy often requires multiple treatments resulting in the
generation of neutralising antibodies, mostly against the PE38
portion of the molecule (Hassan et al, 2004). A potential solution
to this problem was recently published by Onda and Pastan who
showed that there are only seven major B-cell epitopes on the PE38
molecule (Onda et al, 2006). Subsequently, they described a series
of mutations that did not alter the catalytic activity of PE38 yet
nearly eliminated the immune response of mice (Onda et al, 2008).
In these studies, they show that the mouse is a valid model of anti-
toxin immunogenicity.
We have synthesised a unique class of single-chain biological
agents called bispecific ligand-directed toxin (BLT) with significant
advantages over traditional monospecific ligand-directed toxins
including increased potency, broader tumour targeting, and
decreased toxicity (Vallera et al, 2005b, 2008, 2009; Stish et al,
2007a,b, 2008). In this study, we reveal for the first time that
EGF4KDEL, a BLT targeting both EGFR and IL-4R, shows potent
activity against MM both in vitro and in vivo and has significantly
reduced toxicity when given therapeutically. Furthermore, we
show the benefit of readily modifiable biological agents by
synthesising a genetically mutated form of EGF4KDEL with
decreased immunogenicity. This new molecule, EGF4KDEL
7Mut, retained the ability to selectively kill MM tumours while
producing a significantly decreased neutralising antibody response
when injected into Balb/c mice. Our research shows significant
anti-cancer properties of EGF4KDEL 7Mut and its potential for
clinical treatment of mesothelioma.
MATERIALS AND METHODS
Construction of EGF4KDEL and EGF4KDEL 7Mut
Synthesis and assembly of hybrid genes encoding the single-chain
EGF4KDEL was accomplished using DNA-shuffling and DNA-
cloning techniques. The fully assembled fusion gene (from 50 end
to 30 end) consisted of an Nco1 restriction site, an ATG initiation
codon, the genes for human EGF and circularly permutated human
IL-4 linked by a 20 amino-acid segment of human muscle aldolase
(HMA), the 7 amino-acid EASGGPE linker and the first 362 amino
acids of the PE molecule with KDEL replacing the REDLK at the C
terminus, a NotI restriction site at the 30 end of the construct. The
HMA segment was incorporated into the molecule as a flexible,
non-immunogenic linker (Vallera et al, 2005b). The gene-encoding
circularly permuted IL-4 was generously provided by Drs RJ Kreitman
and I Pastan (NIH, Bethesda MD, USA). The resultant 1752bp
NcoI/NotII fragment gene was spliced into the pET21d bacteria expres-
sion vector under control of an isopropyl-b-D-thiogalactopyranoside
inducible T7 promoter (Figure 1). DNA sequencing analysis
(Biomedical Genomics Center, University of Minnesota) was used to
verify that the gene was correct in sequence and had been cloned in
frame. To create an EGF4KDEL molecule with decreased immuno-
genicity, eight amino acids representing the seven major epitopes
on PE38 (Onda et al, 2008) were mutated using the QuickChange
Site-Directed Mutagenesis Kit (Stratagene. La Jolla CA, USA). The
following amino acids were altered: R490A, R513A, R467A, E548S,
K590S, R432G, Q332S, R313A and confirmed with DNA sequencing.
Genes for monospecific cytotoxins splicing mutated PE38(KDEL) to
human EGF (EGFKDEL) and mutated human IL-4 (cpIL4KDEL) were
created using the same techniques. BIC3KDEL, a bispecific immuno-
toxin-targeting T-cell surface marker CD3, was made by replacing
the DT390 portion of the BIC3 molecule described previously with
PE38(KDEL) (Vallera et al, 2005a).
Isolation of inclusion bodies, refolding and purification
Proteins were produced as described previously (Vallera et al,
2008) with some minor modifications to improve yield and purity.
Then, 10mgml
 1 of dithierythritol was included in refolding buffer
to decrease protein aggregation. In addition, refolded protein was
directly diluted instead of being dialysed before loading onto an ion
exchange column. Finally, the purity of protein isolated from the
ion exchange column was further enhanced using an FPLC and
Supradex 200 size exclusion column (Sigma, Ronconcoma, NY,
USA). This modified protocol resulted in a yield of 5–10mg of
protein per litre of culture and a final product with 495% purity.
Cell culture
The human malignant mesothelioma cell lines H2373, H513, and
H2461, as well as the SV40-transformed normal mesothelial cell
line MeT-5A were obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA) and have been described
previously (Pass et al, 1995). MM cell lines were grown as
monolayers in RPMI-1640 media (Cambrex, East Rutherford,
NJ, USA) supplemented with 10% fetal bovine serum, 2mmoll
 1
L-glutamine, 100unitsml
 1 penicillin, and 100mgml
 1 strepto-
mycin. MeT-5A cells were cultured in Medium 199 supplemented
with 10% FBS, 2mmoll
 1 L-glutamine, 3.3nM EGF, 400nM hydro-
cortisone, and 870nM insulin. LP-9, a normal non-immortalized
human mesothelial cell line, was obtained from the NIA Aging
Cell Culture Repository at the Coriell Institute (Camden, NJ, USA)
and was maintained in a Ham’s F12/Medium 199 mixture supple-
mented with 10% fetal bovine serum, 2mmoll
 1 L-glutamine,
0.4mgml
 1 hydrocortisone, and 10ngml
 1 epidermal growth
factor. HPB–MLT, a human T-cell leukaemia cell line, was used
as a negative control and has been described previously (Vallera
et al, 2005a).
For in vivo experiments, H2373 and H513 cells were stably
transfected with dual vectors containing both the firefly luciferase
(Luc) and green fluorescent protein (GFP) genes, as well as a
blastocidin resistance gene (Clontech Laboratories, Mountain
View, CA, USA). Transfection was performed with Lipofectamine
reagent (Invitrogen, Carlsbad, CA, USA) and stable clones were
established using a FACSDiva flow cytometer (University of
Minnesota Flow Cytometry Core Facility of the Masonic Cancer
Center) to seed individual GFP-positive cells into a 96-well plate.
Each clone used in this study, H2373/Luc/GFP and H513/Luc/GFP,
retained identical morphological and biological properties to the
specific parental cell line.
Bioassays to measure in vitro protein synthesis inhibition
To determine the effect of EGF4KDEL on malignant mesothelioma
cells, assays measuring protein synthesis via
3H-leucine incorpora-
tion were conducted. Cells (10
4 per well) were added to a 96-well
flat-bottomed plate in leucine-free media (Caisson Labs, North
Logan, UT, USA) and incubated overnight at 371C with 5% CO2 to
allow cells to adhere. Leucine-free solutions of cytotoxins in varying
concentrations were added to wells in triplicate. Incubation conti-
nued for 72h with
3H-leucine (GE Healthcare, Chalfont St Giles,
UK) added (1mCi per well) for the final 24h of incubation. Plates
were frozen to detach cells and cells were then harvested onto
a glass fibre filter, washed, dried, and counted using standard
scintillation methods. Data from protein synthesis assays are
reported as percentage of control (media alone) c.p.m./20000 cells.
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inhibit protein synthesis by 50% compared with media alone.
Effect of EGF4KDEL on HPB-MLT cells was determined using a
proliferation assay measuring
3H-thymidine incorporation. For
this assay, cells (2 10
4 per well) were mixed with cytotoxins
and incubation continued for 72h. Methyl-[
3H]-thymidine (GE
Healthcare) at a concentration of1mCi per well was added for the
final 8h of incubation. Data collection and analysis proceeded as
described above.
Blocking studies were conducted to test the functionality of
both the EGF and IL-4 ligands on the EGF4KDEL molecule. Briefly,
10nM of concentrations of either recombinant EGF and IL-4
(manufactured as described above) or a combination of both
was added to leucine-free media containing 0.01nM EGF4KDEL.
Resulting mixtures were added to wells containing H513 cells
and protein synthesis was measured as described above. Here,
2219, a recombinant bispecific scFv targeting the CD22 and CD19
B-cell surface molecules was included as a negative control
(Vallera et al, 2005b).
Flow cytometry analysis of EGF4KDEL binding
To measure binding to MM and normal cell lines, EGF4KDEL and
AHN-12 (negative control) were labelled with fluorescein isothio-
cyanate (FITC) as described previously (Stish et al, 2007a). FITC-
labeled proteins at a final concentration 1000nM were incubated with
1 10
6 cells in 100mlo fP B S þ2% FBS on ice for 30min to allow
binding. Following incubation cells were washed three times and
binding was measured using FACSCalibur and CellQuest software
(BD Biosciences, San Jose, CA, USA). Mean fluorescence index (MFI)
of EGF4KDEL-specific binding was determined by subtracting the
mean fluorescence of cells incubated with AHN-12 from that of cells
incubated with EGF4KDEL.
Determining immunogenicity of EGF4KDEL and
EGF4KDEL 7Mut in Balb/c mice
Mouse immunisation studies were utilised to determine whether
EGF4KDEL 7Mut elicited less of an immune response than the
original EGF4KDEL molecule. Female Balb/c mice (n¼6/group)
were injected once weekly with 1mg of either EGF4KDEL or
EGF4KDEL 7Mut for 4 weeks. Five days after the final injection
mice were euthanized and blood was collected via cardiac
puncture. Serum from each mouse was isolated using centrifuga-
tion and frozen. The amount of anti-PE38KDEL IgG in each serum
sample was measured using indirect ELISA. Briefly, 5mgo f
purified recombinant PE38KDEL was added to each well of a
96-well microtiter plate and adhered overnight at 41C. Unbound
protein was washed away with PBS-T and blocking was performed
for 1h with 5% milk/PBS-T. Serum samples were diluted in
1:10000 and 100ml of each was added to appropriate wells
in triplicate. Following 3h incubation, each well was washed
3  with PBS-T. Peroxidase-conjugated rabbit anti-mouse IgG
(Sigma) was added to each well for a 2h room temperature
incubation. Following washing o-Phenylenediamine dihydrochlo-
ride substrate was added to each well. After 30min, the absorbance
at 490nm was measured for each well using a microplate reader.
Quantitation of actual anti-PE38KDEL IgG present in each sample
Cell Line-Histological type IC50
H2052-Sarcomatoid 0.35 nM
H2373-Sarcomatoid 1.3x10
–5 nM
H2461-Epithelioid 5.2x10–4 nM
H2596-Sarcomatoid 0.03 nM
H513-Epithelioid 1.6x10
–6 nM
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Figure 1 In vitro cytotoxicity and specificity of EGF4KDEL. (A) The activity of EGF4KDEL was tested against the human MM cell line H2373 in a protein
synthesis inhibition assay. The effects of EGF4KDEL, EGFKDEL, IL4KDEL, and the T-cell targeting BIC3KDEL were determined by analysing
3H-leucine uptake
by H2373 cells following a 72-h incubation with each agent. Data are reported as percent control response as determined by (
3H-leucine activity of treated
cells/
3H-leucine activity of H2373 cells in media alone)  100. Each data point represents an average of triplicate measures±s.d. (B) Effect of EGF4KDEL on
a panel of different human MM cell lines as measured by protein synthesis inhibition assay. IC50 values represent the concentration required to inhibit 50% of
protein synthesis compared with untreated controls. A cartoon showing the construction of the EGF4KDEL 7mut gene is also shown. (C) In vitro specificity
of EGF4KDEL was shown by testing its activity towards EGFR
 /IL-4R
  HPB-MLT leukaemic T cells in a
3H-thymidine incorporation assay. BIC3KDEL was
included as a positive control. (D) A blocking assay was performed to prove the functionality of each fragment of the EGF4KDEL molecule. H513 cells were
incubated with 0.01nM EGF4KDEL and the effect of blocking with a 10nM concentration of recombinant EGF and IL-4, both separately and in combination
was determined by measuring protein synthesis. The non-binding bispecific recombinant 2219 scFv molecule was included as a specificity control. Data is
presented as a mean of triplicate measures±s.d. and was calculated as percentage of protein synthesis relative to cells incubated with antibodies alone.
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swas determined by comparing the absorbance values in each well
to a standard curve prepared using Protein-A-purified mouse anti-
PE38KDEL.
In vivo efficacy of EGF4KDEL and EGF4KDEL 7Mut against
xenograft models of peritoneal malignant mesothelioma
Male nu/nu mice were purchased from the National Cancer
Institute, Frederick Cancer Research and Development Center,
Animal Production Area and housed in an Association for
Assessment and Accreditation of Laboratory Animal Care-
accredited specific pathogen-free facility under the care of the
Department of Research Animal Resources, University of Minne-
sota. Animal research protocols were approved by the University
of Minnesota Institutional Animal Care and Use Committee. All
animals were housed in microisolator cages to minimise the
potential of horizontal contamination.
Mice were imaged in real time and images were captured
using Xenogen Ivis imaging system (Xenogen Corporation,
Hopkington, MA, USA) and analysed IGOR Pro 4.09a software
(WaveMetrics Inc., Portaland, OR, USA). Before imaging, mice
were anaesthetised using isofluorane gas. All mice received 100ml
of a 30mgml
 1 D-luciferin aqueous solution (Gold Biotechnology,
St Louis, MO, USA) as a substrate for luciferase 10min before
imaging. All images represent a 5min exposure time and all
regions of interest are expressed in units of photons/sec/cm
2/sr.
For this study, we modified two previously established xenograft
models of MM (Smythe et al, 1994; Frizelle et al, 2000). In
experiment one, intraperitoneal Mesothelioma tumours were
established by injecting mice with 2 10
6 H2373/Luc/GFP cells
suspended in 0.5ml PBS on day 0. On day 14, luciferase activity
was measured in each mouse to confirm tumour development and
tumour-bearing mice were randomized into either no treatment or
EGF4KDEL treatment groups (n¼6/group). Mice in the treatment
group were given daily 4mg injections of EGF4KDEL in 0.1ml PBS
on days 14,15,16 and treatment was continued QOD from day 20
through 33 (a total of 10 injections given). All treatments were
administered intraperitoneally. Mice were imaged weekly to
monitor tumour growth. On day 43, mice in both no treatment
and EGF4KDEL groups were euthanized and GFP-expressing
tumour colonies in the peritoneum were photographed as an
additional measure of tumour burden. Fluorescent images were
recorded using a Maestro Imaging Station (CRI, Woburn, MA,
USA). Two blinded parties independently determined the number
of GFP-positive tumour colonies on two separate viewings of the
peritoneal cavity and the average of these independent counts were
reported.
A second murine xenograft model of intraperitoneal Meso-
thelioma was established using the H513/Luc/GFP cell line. For
experiment two, tumours were initiated by injecting a 1.0ml
solution of PBS containing 2 10
6 H513/Luc/GFP cells into the
peritoneum on day 0. Luciferase imaging was conducted as
described above. On day 16 tumour-bearing mice were divided
into either a no treatment or EGF4KDEL 7Mut treatment group
(n¼9/group). Mice in the treatment group were given 4mg
injections of EGF4KDEL 7Mut. The first course of treatment with
EGF4KDEL 7mut commenced on day 16 and consisted of an IP
injection of 4mg each day for 4 days MTWTh. Additional courses
commenced on days 22, 28, 38, 45, 59, 65, 71, 78, 86, 92, 99, 107,
134, and 142. Luciferase imaging was conducted weekly to monitor
treatment efficacy.
Statistical analyses
All statistical analysis was performed using Prism 4 (Graphpad
Software, San Diego, CA, USA). Groupwise comparisons of single
data points were made by Student’s t-test. P-values o0.05 were
considered significant.
RESULTS
In vitro efficacy of EGF4KDEL against human MM cells
The ability of EGF4KDEL to kill cultured human MM cells was
determined using the EGFR
þ and IL-4R
þ H2373 cells in a
protein synthesis inhibition assay. Figure 1A shows that EGF4K-
DEL had impressive activity against H2373 as indicated by IC50
value of 1.3 10
 5nM. This assay also shows that the bispecific
EGF4KDEL was more potent when compared with the mono-
specific cytotoxins EGFKDEL (IC50¼4.3 10
 5) and IL4KDEL
(IC50¼4.0 10
 3nM) targeting EGFR or IL-4R, respectively.
BIC3KDEL, a PE38(KDEL)-containing agent targeting the T-cell-
specific CD3 molecule, had no effect on H2373 cells revealing the
specificity of toxin-mediated cell killing. Figure 1B shows that
similar cytotoxicity was measured against five different MM cell
lines in separate assays. Interestingly, EGF4KDEL displayed
significant anti-cancer activity towards cell lines classified in both
the epithelioid and sarcomatoid morphological subtypes of MM.
These data show the in vitro cytotoxicity of EGF4KDEL towards a
range of human MM cell lines.
Specificity of EGF4KDEL
To show EGF4KDEL specificity, we incubated EGFR
  and IL-4R
 
HBP-MLT leukaemic T cells with varying concentrations
of both EGF4KDEL and BIC3KDEL. Figure 1C shows that while
BIC3KDEL possesses excellent cytotoxicity towards these CD3
þ
cells, EGF4KDEL had no effect on cell proliferation. In vitro
blocking assays were also conducted to show that both the
EGF and IL-4 molecules contribute to EGF4KDEL activity.
Figure 1D reveals that the activity of 0.01nM EGF4KDEL towards
H513 cells is only minimally decreased in the presence of
either 10nM recombinant EGF or IL-4 alone. Probably, the
blocking of only one of the two ligand leaves the other available
to bind and kill. However, when both EGF and IL-4 are added in
combination, H513 cell killing was completely abolished.
Conversely, adding a similar concentration of the non-binding
2219 recombinant molecule had no effect on the ability of
EGF4KDEL to inhibit H513 cell protein synthesis. Additional
studies were performed and anti-EGFR or IL-4R antibodies were
used to block EGFRKDEL activity. Each partially blocked (Oh
et al, 2009). These results show that both the EGF and IL-4 ligands
specifically target their respective receptors and each ligand
contributes individually to the binding and subsequent cytotoxi-
city of EGF4KDEL.
Binding of EGF4KDEL to MM cells compared with normal
mesothelium
One advantage ascribed to BLT over traditional chemotherapeutics
is their ability to target and kill malignant cells while
sparing normal tissue. As all BLT cytotoxicity is dependent on
cell surface binding and internalisation, we measured the ligand-
mediated binding to both malignant mesothelioma and normal
mesothelial cells. Cell lines were incubated with a 1000nM solution
of FITC-labeled EGF4KDEL and subsequently analysed using flow
cytometry. Figure 2 shows a lower level of binding to LP-9
and MeT-5A normal mesothelial cells with an MFI of 3.33 and 4.98,
respectively. On the other hand, stronger EGF4KDEL binding to
malignant H2461 cells (MFI¼17.03) was observed, representing a
greater than fivefold increase over LP-9 binding. Similarly,
H513 cells show a 3.7 times greater level of EGF4KDEL binding
(MFI of 12.25) over non-cancerous LP-9 cells. These observations
reveal greater levels of EGF4KDEL binding to MM cells
with overexpressed EGFR and IL-4R compared with normal
mesothelial cells.
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To determine whether a BLT linking both targeting ligands on
the same single-chain molecule had any toxicity advantages over
treating mice with a mixture of the two monospecific agents,
survival of normal mice given varying amounts of EGF4KDEL was
compared with survival of mice given similar doses of an
equimolar mixture of monomeric EGFKDEL and IL4KDEL. Table 1
shows the advantages of having both ligands on the same single-
chain molecule evidenced by the fact that we were able to give
significantly higher doses of the BLT than a mixture of the
monomeric IL4KDEL and EGFKDEL. Although half of the mice
treated with two 0.5mg injections of the EGFKDEL/IL4KDEL
combination did not survive, all mice receiving 2mg of EGF4KDEL
survived without signs of toxicity. In fact, since further
studies revealed that 4mg injections were also tolerated without
weight loss, subsequent efficacy experiments were performed
using a 4mg multiple-dose regimen representing a nearly 10-fold
decrease toxicity compared with the mixture of monospecific
agents. The lack of toxicity from EGF4KDEL treatment is
especially important in a partial on-target model where the
human EGF ligand cross-reacts with native murine EGFR
(Nakagawa et al, 1985).
Efficacy of EGF4KDEL against intraperitoneal H2373
xenografts
To determine the in vivo activity of EGF4KDEL a bioluminescent
intraperitoneal tumour model was developed. Nude mice bearing
H2373 tumours stably expressing firefly luciferase and green
fluorescent protein genes were treated with 10 injections of
EGF4KDEL from day 14 through day 34. Figure 3A shows
representative images comparing luciferase activity in one mouse
treated with EGF4KDEL to an untreated control animal. These
pictures reveal that EGF4KDEL decreased tumour-associated
bioluminescence compared with a mouse receiving no treatment.
Average luciferase activity of all mice in this experiment is shown
in Figure 3B, demonstrating a significant difference (Po0.02)
between mice receiving EGF4KDEL and untreated controls (n¼6/
group). To prove the necessity of toxin-mediated killing,
additional mice were treated with EGF4, a bispecific ligand devoid
of a PE38(KDEL) and the B-cell-targeting agent 2219KDEL made
with the same PE38(KDEL) construct as EGF4KDEL. These animals
showed no decrease in luciferase activity relative to untreated
controls (data not shown) demonstrating the targeted specificity of
BLT activity. One week following the completion of treatment,
tumour burden was analysed in all animals by quantifying
fluorescent tumour colonies as described in the Materials and
Methods. Figure 3C shows photographs of the peritoneal cavities
from two mice in both the EGF4KDEL and no treatment groups.
Whereas the untreated animals have diffuse GFP-positive H2373
tumour colonies, minimal tumours are seen in treated mice. Two
blinded independent observers counted visible tumour colonies
and the results are shown in Figure 3D. EGF4KDEL mice had
90% fewer colonies with an average of 4.8 tumours compared with
47.6 tumours per animal in the untreated control group (Po0.05).
Together, the use of two separate imaging platforms in the H2373
model revealed that EGF4KDEL possesses significant in vivo
activity against human MM.
Mutation of EGF4KDEL to decrease immunogenicity
To decrease the immunogenicity of EGF4KDEL, the seven major
B-cell epitopes on the PE38(KDEL) portion were mutated. We
tested whether these mutations affected the anti-MM activity of
the molecule. Figure 4A shows that EGF4KDEL 7Mut showed
impressive ability to kill H513 cells with an IC50 of 7.3 10
 7nM.
More importantly, the activity of EGF4KDEL 7Mut was nearly
identical to that of the non-mutated EGF4KDEL molecule.
Immunisation studies with immunocompetent BALB/c mice
were conducted to compare the immunogenicity of EGF4KDEL
7Mut to the parental EGF4KDEL molecule. Mice (n¼6/group)
were immunized weekly for a total of 4 weeks. Serum samples from
each animal were analysed using ELISA to detect anti-PE38(KDEL)
IgG. Figure 4B shows that mice injected with the original
EGF4KDEL agent had an average antibody concentration of
1191mgml
 1 compared with just 155mgml
 1 measured in those
receiving EGF4KDEL 7Mut. Thus, mice given multiple injections of
EGF4KDEL 7Mut generated 87% fewer neutralising antibodies
than those injected with an equal amount of parental EGF4KDEL
(P¼0.05).
Table 1 The effect of EGF4KDEL7 on animal mortality
Deaths/total no. of mice
Drug (lg) 2 1 0.5 0.25
EGFKDEL 4/4 3/4 1/4 0/4
IL4KDEL 0/4 0/4 — —
EGFKDEL+IL4KDEL 6/6 4/4 2/4 0/4
EGF4KDEL 0/4 0/4 — —
Normal C57BL/6 mice received an i.p. injection of drug and then 2 days later, a
second injection was given. Toxic deaths occurred within 7 days. Animals were
observed for 3 weeks.
10
0 10
1 10
2 10
3 10
4
100 101 102 103 104 100 101 102 103 104
10
0 10
1 10
2 10
3 10
4
H2461
MFI=17.03
H513
MFI=12.25
LP-9
MFI=3.33
MeT-5A
MFI=4.98
Malignant mesothelioma cells Normal mesothelial cells
Fluorescence
Cell n
umber
= CD45-FITC
(Negative control)
= EGF4KDEL-FITC
200
150
120
90
60
30
0
150
120
90
60
30
0
160
120
80
40
0
150
120
90
60
30
0
Figure 2 Binding of EGF4KDEL to malignant and normal Mesothelial
cells. The binding of EGF4KDEL to malignant mesothelioma (H2461 and
H513) and normal noncancerous mesothelial (LP-9 and MeT-5A) cell lines
was measured using flow cytometry. Cells were incubated with FITC-
labeled EGF4KDEL and analysed using a FACSCalibur. Histograms show
the measured fluorescence of cells incubated with EGF4KDEL (no fill)
compared with those exposed to a control anti-CD45-FITC antibody
(grey fill). Mean fluorescence index (MFI) values represent the median
fluorescence of EGF4KDEL binding minus background fluorescence
measured with the negative control.
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sTreatment of intraperitoneal H513 tumours with
EGF4KDEL 7Mut
EGF4KDEL 7Mut was tested in a second xenograft MM model.
Intraperitoneal tumours were induced by injecting nude mice with
a 1.0ml suspension of 2 10
6 H513/Luc/GFP cells. Mice bearing
established tumours were either injected with EGF4KDEL 7Mut
or left untreated (n¼9/group). The average tumour-associated
luciferase activity from animals in each group is shown in
Figure 4C. This graph shows that treatment of mice with
EGF4KDEL 7Mut significantly reduced the tumour burden
compared with untreated animals (Po0.001). Furthermore,
despite an aggressive treatment regimen in which 15 courses were
administered, no treatment-related toxicity was observed, indi-
cated by unchanged average animal weights in Figure 4D. Figure 5
shows individual tumour-associated luciferase activity from
representative mice in Figure 4C throughout the course of the
experiment. Although the animals in the untreated control group
display clear tumour growth and progression through day 87, mice
receiving EGF4KDEL 7Mut show an excellent response to therapy
indicated by markedly reduced bioluminescence. The biolumines-
cent imaging findings were correlated with histology studies
(H&E-stained tissue samples) taken from all long-term survivors
(day 150). Examination of liver, kidney, gut, spleen, and lung
samples revealed excellent correlation between histological tumour
reduction and levels of bioluminescence supporting the validity of
this imaging model.
DISCUSSION
The original contribution of this research is the development of
EGF4KDEL 7Mut, a promising new anti-mesothelioma agent with
potential for clinical development. By linking EGF and IL-4, two
well-known tumour-targeting ligands, to a truncated pseudomonas
exotoxin A molecule, we created a novel recombinant agent that
showed potent in vitro and in vivo activity. EGF4KDEL showed
receptor-specific picomolar activity against a panel of human MM
cell lines and also induced an impressive decrease in tumour
burden in an aggressive H2373 intraperitoneal xenograft model.
Importantly, through genetic modification we were able to create
EGF4KDEL 7Mut, a second generation BLT with nearly 90% less
immunogenicity that showed impressive in vivo potency against a
highly aggressive and difficult to treat H513 xenograft model
(Frizelle et al, 2000). In addition, toxicity was diminished by
having both ligands on the same single-chain molecule allowing
administration of significantly greater doses of the BLT than a
mixture of the monomeric IL4KDEL and EGFKDEL. These
improvements address major obstacles in the use of biological
drugs and will permit multiple dosings in future clinical studies
increasing the odds of anti-tumour efficacy.
In order for targeted toxins to become viable treatment options
for solid tumour, steps must be taken to decrease their
immunogenicity so that multiple treatments can be given to
sustain high enough serum levels of drug to penetrate the tumour
(Pirker, 1988). Recent clinical trials testing PE38-based anti-cancer
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Figure 3 Efficacy of EGF4KDEL against intraperitoneal H2373 tumours. (A) Images showing the luciferase activity of H2373/Luc/GFP tumours in
individual mice throughout the course of the experiment. Pictures in each row show the weekly luciferase activity observed in a representative untreated
mouse (top) and a representative mouse treated with EGF4KDEL (bottom), (B) Graph depicting the mean measured luciferase activity±s.d. from mice
bearing H2373/Luc/GFP tumours treated with EGF4KDEL compared with untreated controls (n¼6/group). Luciferase activity was measured for a set
region of interest (ROI) and is reported in units of photons/sec/cm
2/sr. Mice in the treatment group were treated with a total of 10 intraperitoneal injections
of 4mg EGF4KDEL given between days 14 and 34. (C) Pictures showing intraperitoneal detection of GFP-positive H2373 tumours following treatment with
EGF4KDEL. Each row of pictures shows representative images of peritoneal contents from two mice in either EGF4KDEL or no treatment control group.
Mice in each group were euthanized following treatment to count the number of tumour colonies per animal. (D) Graph showing average number of
tumour colonies per animal in both the treatment and control group (n¼6/group). Tumour colonies were counted by blinded observers. Bars represent
average number of colonies per animal±s.d. *Comparison of averages by Student’s t-test resulted in P-value o0.05.
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Figure 4 EGF4KDEL 7Mut. (A) H513 cells were incubated with either EGF4KDEL or EGF4KDEL 7Mut for 72h and protein synthesis was measured.
Data is reported as percent control response. Points indicate mean of triplicate measures±s.d. (B) Bar graph showing anti-PE38(KDEL) IgG from the serum
of Balb/c mice (n¼6/group) immunized with either EGF4KDEL or EGF4KDEL 7Mut. Measurements were made using an indirect ELISA and quantification of
antibody levels was determined using a standard curve (not shown, r
240.97) generated with a protein-purified antibody. (C) Graph depicting the average
photons/sec/cm
2/sr of an animal given EGF4KDEL 7Mut or untreated controls (n¼9/group) (Po0.001). Data points indicate mean total bioluminescence
of all mice±s.d., as determined by luciferase imaging. (D) Average weight of mice in EGF4KDEL 7Mut-treated and untreated control group (n¼9/group)
throughout the course of the study. Animal weights were recorded approximately three times per week to monitor any treatment-related toxicity.
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Figure 5 In vivo activity of EGF4KDEL 7Mut against H513 tumours. Photographs of representative mice showing measured luciferase activity of H513/Luc/
GFP tumours in both (A) EGF4KDEL 7mut treatment group and (B) no treatment groups.
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sagents for the treatment of mesothelioma and glioma revealed that
73 and 88% of the patients respectively developed neutralising IgG
antibodies, with one study showing the majority of the antibodies
were directed to the toxin fragment of the molecule (Hassan et al,
2007; Vogelbaum et al, 2007). To address this issue, Onda and
Pastan used serum samples from patients receiving a BL22, a PE38-
containing anti-leukemia agent, to map out regions of the molecule
that elicited the strongest antibody response (Onda et al, 2006). Upon
identifying seven major reactive epitopes, they proved that muta-
tions could be made to these regions without compromising tumour
cell killing (Onda et al, 2008). Thus, we eliminated the same seven
epitopes on our EGF4KDEL molecule using site-directed mutagen-
esis. Studies revealed that this new agent, EGF4KDEL 7Mut, retained
the same potent anti-MM activity of the original molecule. Even more
impressively, mice immunized with EGF4KDEL 7Mut showed a
greater than 80% reduction in anti-PE38 neutralising antibodies.
Additional studies suggest that mice receiving EGF4KDEL 7Mut
generate very little immune response to the binding portion of the
molecule. When the ELISA was run against the entire EGF4KDEL
molecule rather than against only the toxin, IgG levels were similar
(data not shown). The same would be expected clinically as both EGF
and IL-4 are native human cytokines.
One important issue is whether the mouse is a valid model for
patient anti-toxin responses. Onda and Pastan have tested sera
from patients receiving non-mutated PE38-targeted toxins and
found that their anti-PE38 antibodies bind to the same seven B-cell
epitopes defined by the mouse studies and eliminated in
EGF4KDEL 7mut (Onda et al, 2008). This implies that the mouse
model correlates directly to the human antibody response and is
highly useful for immunogenicity studies.
One major advantage offered by recombinant anti-cancer agents
is that their structure and biological activity can be altered. The
ultimate goal of decreasing the immunogenicity of EGF4KDEL was
to improve its pharmacokinetic profile as its efficacy is enhanced
with prolonged exposure to tumour cells, as evidenced by the
advantage of multiple dosings. Formation of neutralising anti-
bodies leads to rapid serum clearance of the drug and precludes
the opportunity to administer additional doses. Conjugation of
polyethylene glycol to targeted toxins has been used as a strategy
to reduce immunogenicity; however, this strategy often leads to a
loss of catalytic activity (Filpula et al, 2007). The direct genetic
modification used in this study eliminates the additional step of
PEGylation and retains the full cytotoxic capability of parental
molecule. Other studies have shown that using genetic engineering
to mutate T-cell-specific epitopes and the proteolytic cleavage site
can improve the pharmacokinetic profile and in vivo efficacy of the
biological drug (Tangri et al, 2005; Weldon et al, 2008). Additional
studies may show that incorporation of similar mutations into
EGF4KDEL 7Mut can further enhance its already potent anti-
tumour activity.
Another issue facing nearly every anti-cancer chemotherapeutic
agent is treatment-related toxicity. BLT is designed to specifically
target surface receptors that are overexpressed on cancer cells,
thereby minimising toxic effects to normal tissue. We have shown
that EGF4KDEL’s cytotoxicity is receptor specific as EGFR-/IL-4R-
HPB-MLT leukaemia cells are unaffected by concentrations as high
as 10nM. The binding studies reveal that MM cell lines have 3- to
5-fold higher levels of EGF4KDEL bound to their surface than
normal human mesothelial cells. This binding preference of
EGF4KDEL for malignant cells was also observed in protein
synthesis inhibition assays. Whereas exposure to 100fM concen-
trations of EGF4KDEL inhibited more than 90% of H513 cell
protein synthesis, the anabolic activity of normal Met-5A cells
incubated with the same amount of BLT was decreased by less than
20% (data not shown). Specific targeting is further evidenced in
in vivo studies by the fact that 18 intraperitoneal injections of
EGF4KDEL 7Mut yielded no toxicity (Figure 5C) in a mouse model
where the human EGF molecule cross-reacts with the murine
EGFR (Nakagawa et al, 1985). Although human IL-4 does not
cross-react with murine IL-4R (Mosmann et al, 1987), Table 1
shows that its presence on EGF4KDEL results in a significantly
improved toxicity profile compared with monospecific EGFKDEL.
This decrease in toxicity may be due to the fact that the larger BLT
molecule exceeds the glomerular basement membrane filtration
capacity, resulting in decreased nephrotoxicity. Further pharma-
cokinetic studies with a full on-target model, such as non-human
primates, would be necessary to fully elucidate the toxicity benefits
of EGF4KDEL 7Mut compared with the monospecific EGFKDEL
and IL4KDEL. Taken together, these studies reveal that the ligand-
directed targeting of EGF4KDEL 7Mut allows maximal MM cell
killing and may minimise collateral toxicity to healthy tissues.
This research shows for the first time that targeting of EGFR and
IL-4R simultaneously with a BLT is a promising therapeutic option in
the treatment of MM. Figure 1A reveals that targeting both receptors
simultaneously with EGF4KDEL leads to more potent cell killing than
targeting either receptor alone. However, the activity of this agent
does not require concomitant overexpression of both EGFR and
IL-4R. As shown by Figure 1D, both the EGF and IL-4 ligands can
contribute individually to the activity of EGF4KDEL, thus broaden-
ing the utility of this agent, allowing it to target tumours expressing
varying amounts of EGFR or IL-4R in combination or individually.
Despite the fact that greater than 75% of MM tumour samples
overexpressed EGFR, clinical trials targeting EGFR in MM with
tyrosine kinase inhibitors have yielded some objective responses,
but not with the desired frequency (Govindan et al, 2005; Garland
et al, 2007). This inconsistency of response is likely because of the
fact that few MM tumours possess the activating EGFR mutations
that correlate with tyrosine kinase inhibitor efficacy (Cortese et al,
2006). With the mechanism EGF4KDEL cell killing depending on
ligand-mediated binding and internalisation, EGFR mutation
status should not affect BLT-mediated anti-MM activity. Although
targeting of IL-4R in MM has not yet been pursued clinically,
expression studies showed moderate to strong staining in 13 of 13
patient-tumour samples, proving it to be a logical therapeutic
target (Beseth et al, 2004). IL-4R is an ideal candidate for targeted
toxin therapy because of its rapid internalisation upon ligand
binding and limited expression profile in normal tissues
(Kawakami et al, 2002a,b). Numerous preclinical studies have shown
the potent anti-tumour activity of a monospecific cytotoxin
composed of IL-4 linked to PE38 (Kreitman et al, 1994; Shimamura
et al, 2007). However, efficacy of this agent in a Phase I clinical
trial of patients with renal cell carcinoma and NSCLC yielded
no objective tumour responses, likely because of the rapid
development of neutralising antibodies (Garland et al, 2005).
Another important aspect of these studies is the use of in vivo
tumour imaging to assess the therapeutic efficacy of novel BLT in
real time against intraperitoneal models of MM and the observation
of long-term anti-MM affects. Traditionally, treatment outcomes in
intraperitoneal xenograft models of MM were only able to be deter-
mined using expensive long-term survival studies or by euthanizing
animals to count tumour colonies (Frizelle et al, 2000; Stewart et al,
2002). By introducing the firefly luciferase gene into H2373 and
H513 we were able to monitor the effect of treatment on tumour
burden on a weekly basis using a highly sensitive and well-validated
bioluminescent imaging technology that directly correlates with
actual tumour volume (Jenkins et al, 2003). Furthermore, using
H2373 cells stably expressing green fluorescent protein for our
in vivo study, we were able to accurately assess and quantitate
peritoneal tumour colonies at the completion of treatment. This
strategy has been shown to be much more sensitive for detecting and
assessing tumour nodules (Udagawa et al,2 0 0 2 ;O het al, 2009).
The murine model of intraperitoneal human MM is currently
considered the appropriate in vivo model for studying localised
therapy. Despite the fact that only about 11% of clinical
mesothelioma cases are confined to the peritoneum (Hassan
et al, 2006), the model is also considered a well-accepted surrogate
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studies have shown promise for localised intraperitoneal and
intrapleural administration of chemotherapeutics (Hotta et al,
2004; Sterman et al, 2007), most trials have been inconclusive.
Localised administration of EGF4KDEL may offer advantages
in lower systemic toxicity, eased immune response, and greater
tumour targeting. Systemic therapy is currently the standard
of care for treatment of MM. A recent Phase I trial showed
that systemic administration of SS1P, a recombinant-targeted
toxin similar to EGF4KDEL 7Mut, resulted in stable disease or
minor responses in 14 of 19 patients with MM (Hassan et al, 2007).
Our in vivo experiments were conducted with intraperitoneal
injection of EGF4KDEL 7Mut because of the technical difficulties
associated with frequent multiple i.v. injections in mice. These data
reveal that intraperitoneal injection of BLT was highly effective at
decreasing tumour burden in two separate aggressive models of
MM where treatment started 14–16 days post tumour inoculation;
however, further experiments will be needed to compare local
infusion of EGF4KDEL 7Mut to systemic therapy.
In conclusion, EGF4KDEL 7Mut is a powerful new alternative
therapy for drug refractory MM. Our in vitro studies show this
drug exhibits potent and selective activity. More importantly, we
reduced in vivo drug toxicity and by introducing a series of amino-
acid substitutions, we were able to decrease the immunogenicity of
EGF4KDEL 7Mut and ultimately improve its potential for use in a
clinical setting for MM therapy.
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